Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cannabinoid receptor 1 (brain) | Starlite/ChEMBL | References |
Rattus norvegicus | Cannabinoid CB1 receptor | Starlite/ChEMBL | References |
Homo sapiens | cannabinoid receptor 2 (macrophage) | Starlite/ChEMBL | References |
Rattus norvegicus | Cannabinoid CB2 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | allatostatin A receptor | Cannabinoid CB2 receptor | 360 aa | 363 aa | 22.9 % |
Schistosoma mansoni | biogenic amine (5HT) receptor | Cannabinoid CB2 receptor | 360 aa | 370 aa | 23.5 % |
Onchocerca volvulus | Phospholipase d-related homolog | Cannabinoid CB2 receptor | 360 aa | 309 aa | 23.3 % |
Echinococcus multilocularis | neuropeptide receptor | Cannabinoid CB2 receptor | 360 aa | 299 aa | 24.7 % |
Echinococcus multilocularis | allatostatin A receptor | Cannabinoid CB2 receptor | 360 aa | 342 aa | 22.8 % |
Schistosoma mansoni | opsin-like receptor | Cannabinoid CB2 receptor | 360 aa | 314 aa | 22.0 % |
Loa Loa (eye worm) | neuropeptide F receptor | Cannabinoid CB2 receptor | 360 aa | 348 aa | 24.7 % |
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 327 aa | 19.6 % | |
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 389 aa | 21.1 % | |
Echinococcus granulosus | neuropeptide receptor | Cannabinoid CB2 receptor | 360 aa | 337 aa | 24.0 % |
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 330 aa | 20.9 % | |
Schistosoma japonicum | ko:K04209 neuropeptide Y receptor, invertebrate, putative | Cannabinoid CB2 receptor | 360 aa | 311 aa | 20.6 % |
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 297 aa | 21.9 % | |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | Cannabinoid CB2 receptor | 360 aa | 360 aa | 23.1 % |
Schistosoma mansoni | peptide (allatostatin)-like receptor | Cannabinoid CB2 receptor | 360 aa | 323 aa | 22.6 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Cannabinoid CB2 receptor | 360 aa | 370 aa | 23.8 % |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | = 38 % | Displacement of [3H]CP-55940 from human CB1 receptor expressed in CHO cell membrane at > 10 uM after 90 mins by scintillation counting analysis | ChEMBL. | 23697626 |
Activity (functional) | = 45 % | Inverse agonist activity at human CB2 receptor expressed in CHO cell membrane assessed as increase in forskolin-stimulated cAMP production at 1 uM by scintillation counting analysis relative to WIN55212-2 | ChEMBL. | 23697626 |
Activity (binding) | = 47 % | Displacement of [3H]CP-55940 from Sprague-Dawley rat brain CB1 receptor at > 10 uM after 90 mins by scintillation counting analysis | ChEMBL. | 23697626 |
Activity (functional) | = 65 % | Inverse agonist activity at human CB2 receptor expressed in CHO cell membrane assessed as increase in forskolin-stimulated cAMP production at 10 uM by scintillation counting analysis relative to WIN55212-2 | ChEMBL. | 23697626 |
Ki (binding) | = 52 nM | Displacement of [3H]CP-55940 from human CB2 receptor expressed in CHO cell membrane after 60 mins by scintillation counting analysis | ChEMBL. | 23697626 |
Ki (binding) | = 60 nM | Displacement of [3H]CP-55940 from Sprague-Dawley rat spleen CB2 receptor after 60 mins by scintillation counting analysis | ChEMBL. | 23697626 |
Ki (binding) | > 10000 nM | Displacement of [3H]CP-55940 from human CB1 receptor expressed in CHO cell membrane after 90 mins by scintillation counting analysis | ChEMBL. | 23697626 |
Ki (binding) | > 10000 nM | Displacement of [3H]CP-55940 from Sprague-Dawley rat brain CB1 receptor after 90 mins by scintillation counting analysis | ChEMBL. | 23697626 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.